Symbol classroom

IDYA

Chart the move, read why OppHub America is covering it, then watch or talk it through — not a Google Finance clone.

IDYA

TradingView chart · search any symbol inside the widget · informational only

Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice

0 watching· join free Discuss in Community Join Community

Learn the move

Use this page as a short classroom: (1) scan the chart for the recent move, (2) read OppHub America Insider / Policy / company notes on IDYA, (3) note what to watch next, then (4) add IDYA to Watch or take the conversation to Community / Club.

Money angle — If I Biosciences maintains its balance sheet runway into 2030 backed by $1.24 billion in cash and marketable securities, watch clinical trial milestones because retaining 100% of high-margin . commercial rights impacts long-term valuation.

Latest coverage on IDYA

Recent OppHub America stories tagged IDYA — Insider, Policy, CEO Desk, and market catalysts

IDYA Form 4 insiders →IDYA policy →CEO Desk →Explore →

PolicySeptember 25, 2026

If IDEAYA Biosciences·$IDYA

SPDR S&P 500 ETF·$SPY

IDEAYA Biosciences (IDYA) Q3 Balance Sheet and R&D Spend

IDEAYA Biosciences (NASDAQ: IDYA) reported wider quarterly net losses alongside $1.24 billion in cash and marketable securities on Friday, September 25, 2026. Investors are evaluating how clinical trial investments and retained U.S. commercial rights impact oncology valuation models.

oil gasutilitiesclean energy

If I Biosciences maintains its balance sheet runway into 2030 backed by $1.24 billion in cash and marketable securities, watch clinical trial milestones because retaining 100% of high-margin . commercial rights impacts long-term valuation.

Read desk note →Chart If IDEAYA Biosciences $IDYA

StorySeptember 25, 2026

$IDYA

IDEAYA Biosciences Grants Equity Awards Under Nasdaq Rule 5635(c)(4)

IDEAYA Biosciences (NASDAQ: IDYA) announced on Friday, September 25, 2026, that its Compensation Committee approved inducement stock options on September 24, 2026, featuring an exercise price of $36.74 per share. Traders tracking equity compensation events should note the four-year vesting schedule tied to these grants.

If tracking equity dilution and compensation metrics, monitor the $36.74 exercise price reference point set on September 24, 2026.

Read desk note →Chart $IDYA

PolicySeptember 25, 2026

$IDYA

IDYA Stock: IDEAYA Biosciences Issues Inducement Grants

Precision medicine firm IDEAYA Biosciences (NASDAQ: IDYA) granted non-qualified stock options for 94,000 shares to three new hires on September 24, 2026, under Nasdaq Listing Rule 5635(c)(4). The inducement options carry a $36.74 strike price matching the closing level on the grant date.

oil gasutilitiesclean energy

If maintains technical stability above its recent grant valuation benchmark of $36.74, traders watch for broader oncology pipeline milestones in components.

Read desk note →Chart $IDYA

Same-sector peers

Compare nearby names in the classroom

Trade this symbol

End-of-day delayed data · not investment advice · some links are affiliate / referral